Hemady (dexamethasone tablets) / Dexcel Pharma - LARVOL DELTA

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | N=100 ➔ 16 | Trial completion date: Dec 2028 ➔ May 2027 | Trial primary completion date: Dec 2028 ➔ May 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Emory University | Trial completion date: Oct 2027 ➔ Oct 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • CD4

FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P1 trial • Brain Cancer • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor

AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P3 | N=352 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial primary completion date: Sep 2027 ➔ Jun 2026

Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • CSF1R • PDGFRA • PDGFRB

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov) - P2 | N=74 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2026 ➔ Apr 2027

Enrollment open • Trial initiation date • Hematological Malignancies • Leukemia • Oncology • Plasma Cell Leukemia

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (clinicaltrials.gov) - P1/2 | N=162 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2026 ➔ Mar 2029 | Initiation date: Jul 2026 ➔ Apr 2027 | Trial primary completion date: Aug 2026 ➔ Mar 2029

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

SWOG S0777: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - P3 | N=525 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Jun 2027

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (clinicaltrials.gov) - P1/2 | N=53 | Active, not recruiting | Sponsor: Columbia University | Recruiting ➔ Active, not recruiting

Enrollment closed • Amyloidosis

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=19 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=36 ➔ 19 | Trial completion date: Sep 2026 ➔ Jul 2027

Enrollment change • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (clinicaltrials.gov) - P1/2 | N=53 | Recruiting | Sponsor: Columbia University | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Amyloidosis

NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=3 | Completed | Sponsor: Elvira Umyarova | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology • SLAMF7

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Jun 2028 | Trial primary completion date: Jun 2026 ➔ Jun 2028

Trial completion date • Trial primary completion date • Amyloidosis • Multiple Myeloma • BCL2

Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: SWOG Cancer Research Network

New P2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD19 • KMT2A

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (clinicaltrials.gov) - P2 | N=74 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P2 trial • Hematological Malignancies • Leukemia • Oncology • Plasma Cell Leukemia

AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - P3 | N=5949 | Completed | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2026 ➔ Mar 2026 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • ETV6 • KMT2A • RUNX1

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Terminated ➔ Active, not recruiting | N=19 ➔ 36 | Trial completion date: Nov 2023 ➔ Sep 2026 | Trial primary completion date: Nov 2023 ➔ Sep 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: Elvira Umyarova | Trial primary completion date: Aug 2026 ➔ May 2026

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • SLAMF7

AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov) - P3 | N=9350 | Completed | Sponsor: Children's Oncology Group | Active, not recruiting ➔ Completed

Trial completion • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Childhood B Acute Lymphoblastic Leukemia • Developmental Disorders • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Lung-MAP Non-Match Sub-Study: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (clinicaltrials.gov) - P2/3 | N=82 | Active, not recruiting | Sponsor: SWOG Cancer Research Network | Trial primary completion date: Feb 2027 ➔ Jun 2027

Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • NTRK • ROS1

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Enrollment closed • Amyloidosis • Multiple Myeloma • BCL2

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=19 | Terminated | Sponsor: National Cancer Institute (NCI) | N=36 ➔ 19 | Active, not recruiting ➔ Terminated; Other - Drug supply issues and withdrawal of company support.

Enrollment change • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial (clinicaltrials.gov) - P1/2 | N=10 | Active, not recruiting | Sponsor: University of Southern California | Trial primary completion date: Aug 2026 ➔ Dec 2026

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Radiosurgery Before Surgery for the Treatment of Brain Metastases (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed | Trial completion date: Feb 2027 ➔ Mar 2026

Trial completion • Trial completion date • Oncology • Solid Tumor

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Abdullah Khan | Recruiting ➔ Active, not recruiting | N=27 ➔ 12

Enrollment change • Enrollment closed • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • CRBN • IKZF1